Progress in advanced cellular and gene therapies in South Africa and barriers to patient access: A National Consortium paper on behalf of the BloodSA Cell and Gene Therapy working party
DOI:
https://doi.org/10.7196/SAMJ.2025.v115i5.3070Keywords:
cellular therapies; gene therapies; advanced cell and gene therapies; equitable access;Abstract
The fields of molecular and cellular medicine have, in recent years, witnessed a great deal of progress globally, particularly in understanding disease pathogenesis and through the development of advanced cellular therapy products and gene therapies. Despite the transformative potential of these new therapies, low- and middle-income countries face significant barriers to their access. Advanced cellular therapy legislation in South Africa (SA) has not kept up with this fast-advancing field, and requires a fast-tracked renewal. Furthermore, the prohibitive cost of commercial therapies, including chimeric antigen receptor (CAR) T-cell products, and the lack of infrastructure, manufacturing and research capacity, must be addressed to make equitable patient access an achievable goal in our setting. To this end, a national cell and gene therapy consortium, comprising clinicians, clinician-scientists, scientists, legal experts, postgraduate students and representatives from industry, the national blood service and the pharmaceutical industry, was initiated. The mandate of this group is to aid the progression of advanced cellular therapies in SA, and the purpose of this article is to outline the progress that has been made. We will highlight the gaps in each core field of practice within this space, and provide a proposal for making these therapies more accessible in SA.
References
1. Viljoen IM, Hendricks CL, Malherbe HL, Pepper MS. Regenerative medicines: A new regulatory paradigm for South Africa. Biochimie 2022;196:123-130. https://doi.org/10.1016/j.biochi.2022.02.010
2. MasonC,DunnillP.Abriefdefinitionofregenerativemedicine.RegenerativeMed2008;3(1):1-5.
3. LeMaistre CF, Farnia S, Crawford S, et al. Standardisation of terminology for episodes of hematopoietic stem cell patient transplant care. Biol Blood Marrow Transplant 2013;19(6):851-857. https://doi.
org/10.1016/j.bbmt.2013.03.004
4. Du S, Yan J, Xue Y, Zhong Y, Dong Y. Adoptive cell therapy for cancer treatment. Exploration 2023;3(4):20210058. https://doi.org/10.1002/EXP.20210058
5. American Society of Gene and Cell Therapy. Gene, Cell, + RNA Therapy Landscape Report Q1 2024. Quarterly Data Report 2024. https://www.asgct.org/global/documents/asgct-citeline-q1-2024-report. aspx (accessed 29 September 2024).
6. Mahlangu J, Kaczmarek R, von Drygalski A, et al. Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A. N Engl J Med 2023;388(8):694-705. https://doi.org/10.1056/nejmoa2211075
7. PipeSW,LeebeekFWG,RechtM,etal.GenetherapywithetranacogenedezaparvovecforhemophiliaB.
N Engl J Med 2023;388(8):706-718. https://doi.org/10.1056/nejmoa2211644
8. Von Drygalski A, Gomez E, Giermasz A, et al. Stable and durable factor IX levels in patients with
hemophilia B over 3 years after etranacogene dezaparvovec gene therapy. Blood Adv 2023;7(19):5671-
5679. https://doi.org/10.1182/bloodadvances.2022008886
9. Leavitt AD, Konkle BA, Stine KC, et al. Giroctocogene fitelparvovec gene therapy for severe hemophilia
A: 104-week analysis of the phase 1/2 Alta study. Blood 2024;143(9):796-806. https://doi.org/10.1182/
blood.2022018971
10. PaximadisM,MathebulaTY,GentleNL,etal.HumanleukocyteantigenclassI(A,B,C)andII(DRB1) diversity in the black and Caucasian South African population. Hum Immunol 2012;73(1):80-92. https:// doi.org/10.1016/j.humimm.2011.10.013
11. TshabalalaM,MelletJ,VatherK,etal.HighresolutionHLA~A,~B,~C,~DRB1,~DQA1,and~DQB1 diversity in South African populations. Front Genet 2022;13. https://doi.org/10.3389/fgene.2022.711944
12. Viljoen IM, Hendricks CL, Mellet J, Pepper MS. Perspectives on establishing a public cord blood
inventory in South Africa. Cytotherapy 2021;23(6):548-557. https://doi.org/10.1016/j.jcyt.2021.02.116
13. Hendricks CL, Alessandrini M, Pepper MS. Equitable access to cell and gene therapies in South Africa: Opportunities and hurdles. Gene Ther 2022;30(1-2):1-7. https://doi.org/10.1038/s41434-021-00309-y
14. Viljoen I, Pepper M. Addressing the limitations of the regulatory landscape in South Africa regarding
advanced cell and gene therapies and related sectors involving human cells, tissues and organs. S Afr
Med J 2025;115(1):e2629.
15. South Africa. Medicines and Related Substances Control Act 101 of 1965 after amendment by the
Medicines and Related Substances Control Amendment Act (Act 90 of 1997). https://www.afma.co.za/ download/act-101-of-1965-amendment/?wpdmdl=1337&refresh=675323f4734701733501940 (accessed 6 December 2024).
16. South Africa. National Health Act No. 61 of 2003. https://www.gov.za/sites/default/files/gcis_ document/201409/a61-03.pdf (accessed 6 December 2024).
17. South Africa. Genetically modified organisms Act No. 15 of 1997. https://www.gov.za/sites/default/ files/gcis_document/201409/act15of1997.pdf (accessed 6 December 2024).
18. Viljoen IM, Pepper MS. When cells become medicines: A South African perspective. S Afr Med J 2021;111(11):1055-1059. https://doi.org/10.7196/SAMJ.2021.V111I11.15990
19. Arbuthnot P, Maepa MB, Ely A, Pepper MS. The state of gene therapy research in Africa, its significance and implications for the future. Gene Ther 2017;24(9):581-589. https://doi.org/10.1038/ gt.2017.57
20. Cornetta K, Bonamino M, Mahlangu J, Mingozzi F, Rangarajan S, Rao J. Gene therapy access: Global challenges, opportunities, and views from Brazil, South Africa, and India. Molecular Therapy 2022;30(6):2122-2129. https://doi.org/10.1016/j.ymthe.2022.04.002
21. ESSENCE on Health Research. Seven principles for strengthening research capacity in low- and middle-income countries: Simple ideas in a complex world. Geneva: TDR/World Health Organization, 2014. https://tdr.who.int/publications/m/item/2014-06-19-seven-principles- for-strengthening-research-capacity-in-low-and-middle-income-countries-simple-ideas-in-a- complex-world (accessed 28 January 2025).
22. Whitworth JA, Kokwaro G, Kinyanjui S, et al. Strengthening capacity for health research in Africa. Lancet 2008;372(9649):1590-1593. https://doi.org/10.1016/S0140-6736(08)61660-8
23. Squires A, Chitashvili T, Djbouti M, Ridge L, Chyun D. Health research capacity building in Georgia: A case-based needs assessment. Public Health 2017;147(2017):1-7. https://doi.org/10.1016/j. puhe.2017.01.024
24. KamauC,PrinsenL,ThaldarD.Benefit-sharingwithhumanparticipantsinhealthresearchinSouth Africa: A call for clarity. Dev World Bioeth 2024;1-10. https://doi.org/10.1111/dewb.12456
25. Phacilitate. Unlock the future of advanced therapeutics: Considerations for developing global manufacturing capacity. Phacilitate, 2023. https://www.bigmarker.com/phacilitate/unlock-the- future-of-advanced-therapeutics-considerations-for-developing-global-manufacturing-capacity (accessed 28 January 2025).
26. Moretti A, Ponzo M, Nicolette CA, Tcherepanova IY, Biondi A, Magnani CF. The past, present, and future of non-viral CAR T Cells. Front Immunol 2022;13:867013. https://doi.org/10.3389/ fimmu.2022.867013
27. Mallapaty S. Cutting-edge cancer therapy is made in India – at one-tenth the cost. Nature News Focus 2024;627:709-710.
28. Juckett LA, Bunger AC, McNett MM, Robinson ML, Tucker SJ. Leveraging academic initiatives to advance implementation practice: A scoping review of capacity building interventions. Implementation Sci 2022;17:49. https://doi.org/10.1186/s13012-022-01216-5
29. DavidsN.Sub-SaharanAfricaindesperateneedofclinicalhaematologists.CapeTown:UCTNews, 2021. https://www.news.uct.ac.za/article/-2021-05-06-sub-saharan-africa-in-desperate-need-of- clinical-haematologists (accessed 20 August 2024).
30. World Health Organization. Global Health Workforce statistics database. Geneva: WHO, 2024. https://www.who.int/data/gho/data/themes/topics/health-workforce (accessed 20 August 2024). 31. WongCH,LiD,WangN,GruberJ,LoAW,ContiRM.Theestimatedannualfinancialimpactofgene
therapy in the United States. Gene Ther 2023;30(10-11):761-773. https://doi.org/10.1038/s41434-
023-00419-9
32. McDonald M, Woodworth I. Cell and gene innovative payment models in the US – will they stick? zs.com, 29 April 2024. https://www.zs.com/insights/innovative-payment-models-cell-and-gene- therapies (accessed 28 January 2025).
33. Faulkner E, Werner M, Falb R. Roadmap for navigating cell and gene therapy value demonstration and reimbursement in US managed care: Reimbursement roadmap monograph 2019. Tel, 2019. https://alliancerm.org/wp-content/uploads/2020/05/ARMMonograph2019.pdf (accesssed 28 January 2025)
34. Choe JH, Abdel-Azim H, Padula W V, Abou-El-Enein M. Cost-effectiveness of axicabtagene ciloleucel and tisagenlecleucel as second-line or later therapy in relapsed or refractory diffuse large B-cell lymphoma. JAMA Netw Open 2022;5(12):e2245956. https://doi.org/10.1001/ jamanetworkopen.2022.45956
35. Kelkar HA, Cliff ERS, Jacobson CA, et al. Cost-effectiveness of CD19 chimeric antigen receptor T-cell (CAR-T) therapy versus autologous stem cell transplantation (ASCT) for high-risk diffuse large B-cell lymphoma (DLBCL) in first relapse. JCO 2022;40:7537. https://doi.org/10.1200/ JCO.2022.40.16_suppl.7537
36. Potnis KC, Di M, Isufi I, et al. Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma. Blood Adv 2023;7(5):801-810. https://doi. org/10.1182/bloodadvances.2022008097
37. Wilkins D, Jarboe J, Maria R. Deloitte: Transformative therapies require transformative financing models. Deloitte Development LLC, 2024. https://www2.deloitte.com/content/dam/Deloitte/us/ Documents/life-sciences-health-care/us-cgt-financing-models-pov.pdf (accessed 28 January 2025).
38. Odstrcil MS, Lee CJ, Sobieski C, Weisdorf D, Couriel D. Access to CAR T-cell therapy: Focus on diversity, equity and inclusion. Blood Rev 2024;63:101136. https://doi.org/10.1016/j. blre.2023.101136
39. Ahmed N, Shahzad M, Shippey E, et al. Socioeconomic and racial disparity in chimeric antigen receptor T cell therapy access. Transplant Cell Ther 2022;28(7):358-364. https://doi.org/10.1016/j. jtct.2022.04.008
40. AlHadidiS,SchinkeC,ThanendrarajanS,ZangariM,VanRheeF.Enrollmentofblackparticipants in pivotal clinical trials supporting US Food and Drug Administration approval of chimeric antigen receptor-T cell therapy for hematological malignant neoplasms. JAMA Netw Open 2022;5(4):e228161. https://doi.org/10.1001/jamanetworkopen.2022.8161
Downloads
Published
Issue
Section
License
Copyright (c) 2025 C Hendricks, I Viljoen, M Botes, D Brittain, J Mahlangu, E Verburgh, T Gerdener, C Herd, M Logan, A L Marais, T N Glatt, R Cockeran, C Poole, J Du Toit, M S Pepper
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.
